Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: S&P Capital IQ – STARS Reports
Provider: Stock Traders Daily
Provider: Pechala's Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Valeant Pharmaceuticals International Inc Reaffirms FY 2013 Guidance-Conference Call

Wednesday, 9 Jan 2013 12:30pm EST 

Valeant Pharmaceuticals International Inc announced that in terms of guidance, it announced last week that it expects in terms of revenue, cash EPS and adjusted cash flow from operations, so $4.4 billion to $4.8 billion of revenue, fiscal 2013, cash EPS up also 35%, the $5.45 to $5.75. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report EPS of $4.52 on revenues of $4.6 billion for fiscal 2013. 

Company Quote

-0.84 -0.68%
25 Jul 2014